BD Medical, a segment of Medical technology major
Becton, Dickinson and Company
), has launched a new prefillable polymer syringe, which is
specially engineered to deliver large volume of drugs by
intravenous infusion. Due to its high infusion rate, the syringe
can be used for anesthesia, pain management, cardiac therapy and
nutrition amongst others.
ALIGN TECH INC (ALGN): Free Stock Analysis
ALPHATEC HLDGS (ATEC): Free Stock Analysis
BECTON DICKINSO (BDX): Free Stock Analysis
COOPER COS (COO): Free Stock Analysis Report
To read this article on Zacks.com click here.
The advanced syringe is made with a highly advanced cyclic olefin
polymer that is enable to provide several advantages to drug
manufacturers and healthcare professionals including reduced
breakage, glass-like transparency, and low levels of
extractables. Along with a specific coating technology, this
special type of polymer provides smooth gliding, delivering an
accurate and consistent infusion rate.
The syringe also facilitate a seamless transition for healthcare
workers as its unique design avoids any syringe pump
reprogramming activity for hospitals and helps reduce risks of
administration errors for healthcare workers. Moreover, the
syringe is highly durable, resulting in lower flange breakage and
reliable connection with syringe pumps
Becton, Dickinson and Company reported a marginal 1.3% rise in
third quarter fiscal 2013 adjusted earnings per share from
continuing operations to $1.54, beating the Zacks Consensus
Estimate of $1.47. Revenues went up 3.6% (up 5.1% in constant
currency or CER) to $2,052.7 million, which were marginally ahead
of the Zacks Consensus Estimate of $2,050 million.
At BD Medical, global revenues rose 6.6% (up 7.9% at CER) to
$1140.5 million in the quarter, driven by healthy revenues from
Medical Surgical Systems, Diabetes Care and Pharmaceutical
Becton Dickinson reiterated its guidance for fiscal 2013. The
company expects sales growth for fiscal 2013 in the range of 3.5%
to 4% (growth of 5.0% at CER) compared with 4.5% to 5.0%
BDX also continues to expect reported earnings per share from
continuing operations for fiscal 2013 in a band of $5.72−$5.75.
The projection implies a year-over-year rise of 6.5%−7.0%
(8.5%−9.0% at CER) for fiscal 2013 or 11.0%−11.5% after
accounting for the medical device tax implemented in Jan 2013.
Currently, BDX carries a Zacks Rank #3 (Hold). Other medical
stocks that are worth considering include
Alphatec Holdings, Inc.
The Cooper Companies Inc.
Align Technology Inc.
). These stocks carry a Zacks Rank #2 (Buy).